LONDON, UK I October 14, 2024 I GSK plc (LSE/NYSE: GSK) today announced positive headline results from the phase III clinical trials ANCHOR-1 and ANCHOR-2, ...

CAMBRIDGE, MA, USA & MONTREAL, Canada I October 14, 2024 I Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage ...

REDMOND, WA, USA I October 14, 2024 I SystImmune, Inc (SystImmune), a clinical-stage biotechnology company, announced that the U.S. Food and Drug ...

NEW YORK, NY, USA I October 11, 2024 I Pfizer Inc. (NYSE: PFE)announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...

Dong-A ST’s biologics license application (BLA) for Imuldosa, submitted in October 2023, is approved by the U.S. Food and Drug Administration ...

Approval is based on Phase III INAVO120 results, showing the ItovebiTM (inavolisib)-based regimen more than doubled progression-free survival compared with ...

COPENHAGEN, Denmark I October 10, 2024 I Novo Holdings, a leading global life sciences investor, today announced the launch of Booster Therapeutics (Booster / the Company), a biotechnology company ...

NEW YORK, NY, USA I October 10, 2024 I Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) ...

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program’s ...

October 10, 2024 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...

BEIJING, China I October 09, 2024 I InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and ...

BERLIN, Germany I October 09, 2024 I Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...